Obi1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: OBI1

NCBI ID: G79596

OBI1

Obi1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Obi1 (C13orf7) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. Obi1 is a cytoskeletal protein that is expressed in a variety of tissues, including the brain, pancreas, and heart. It is involved in the formation of microtubules, which are important for cell division and transport of organelles within the cell.

Studies have shown that Obi1 is often expressed in various types of cancer, including lung, breast, and ovarian cancer. It has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

One of the key features of Obi1 is its ability to interact with several other proteins, including the protein Tau. Tau is a well-known protein that is involved in the formation of neurofibrillary tangles, which are a hallmark of Alzheimer's disease. By interacting with Tau, Obi1 has been shown to contribute to the development and progression of neurodegenerative diseases.

Another study has shown that Obi1 is involved in the development of cancer by promoting the growth and survival of cancer cells. This is thought to happen by regulating the cell cycle, which is the process by which cells grow and divide.

In addition to its role in cancer and neurodegenerative diseases, Obi1 has also been shown to be involved in other processes in the body. For example, it has been shown to be involved in the development and maintenance of the nervous system, as well as in the regulation of blood pressure.

Given its involvement in so many different processes in the body, it is not surprising that Obi1 has been identified as a potential drug target. Researchers are currently working to develop small molecules that can inhibit the activity of Obi1 and prevent it from contributing to the development and progression of various diseases. These small molecules may be used to treat a range of conditions, including cancer, neurodegenerative diseases, and other conditions that are characterized by the overgrowth or dysfunction of cells.

In conclusion, Obi1 is a gene that has been identified as a potential drug target and biomarker for a variety of diseases. Its involvement in the formation of microtubules, the development and progression of cancer, and the regulation of various processes in the body make it an attractive target for researchers. Further studies are needed to fully understand the role of Obi1 in these processes and to develop effective treatments for the diseases it is involved in.

Protein Name: ORC Ubiquitin Ligase 1

Functions: E3 ubiquitin ligase essential for DNA replication origin activation during S phase (PubMed:31160578). Acts as a replication origin selector which selects the origins to be fired and catalyzes the multi-mono-ubiquitination of a subset of chromatin-bound ORC3 and ORC5 during S-phase (PubMed:31160578)

The "OBI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OBI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets